{"id":23988,"date":"2021-12-24T07:42:06","date_gmt":"2021-12-24T12:42:06","guid":{"rendered":"https:\/\/capital10x.com\/old\/?p=23988"},"modified":"2021-12-24T10:34:00","modified_gmt":"2021-12-24T15:34:00","slug":"growth-navigator-december-24-2021","status":"publish","type":"post","link":"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/","title":{"rendered":"Capital 10X Growth Navigator &#8211; December 24th 2021"},"content":{"rendered":"<p>Wishing all our readers a very happy holiday season from the Capital 10X team! \ud83c\udf84\u2744\ufe0f<\/p>\n<div style=\"width: 640px;\" class=\"wp-video\"><video class=\"wp-video-shortcode\" id=\"video-23988-1\" width=\"640\" height=\"360\" preload=\"metadata\" controls=\"controls\"><source type=\"video\/mp4\" src=\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2021\/12\/2021-12-24-Growth-Navigator.mp4?_=1\" \/><a href=\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2021\/12\/2021-12-24-Growth-Navigator.mp4\">https:\/\/capital10x.com\/old\/wp-content\/uploads\/2021\/12\/2021-12-24-Growth-Navigator.mp4<\/a><\/video><\/div>\n<h1><span style=\"font-family: verdana, geneva, sans-serif;\">Mining<\/span><\/h1>\n<h2><span style=\"font-family: verdana, geneva, sans-serif;\">Copper Miners on Deep Discount<\/span><\/h2>\n<p><iframe loading=\"lazy\" title=\"Copper Miners on Deep Discount\" width=\"696\" height=\"392\" src=\"https:\/\/www.youtube.com\/embed\/rADXdjy3Ab4?feature=oembed&#038;enablejsapi=1&#038;origin=https:\/\/capital10x.com\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture\" allowfullscreen><\/iframe><\/p>\n<p>Commodities are the cheapest they&#8217;ve ever been relative to stocks in nearly 50 years; and we believe <a href=\"https:\/\/capital10x.com\/old\/copper-miners-on-discount\/\">copper is one of the most attractive<\/a> areas of the commodity complex.<\/p>\n<p>Copper is a critical element for the future green economy; it is a key input for electric vehicles, wind, solar and infrastructure. In the near term there is a very tight supply\/demand dynamic for copper, with global inventories sitting at decade lows.<\/p>\n<p>Additionally, base metal miners are trading at trough valuations relative to history, the group of North American miners currently trade at 4.5x EV\/EBITDA versus their historical average of 6.0x EV\/EBITDA.<\/p>\n<p>The small and mid cap copper mining universe offers the best value in the sector, as they trade at a substantial discount to their large cap copper peers. Sierra Metals (NYSE:SMTS, TSX:SMT) and Hudbay Minerals (TSX:HBM) are two copper miners that screen deep value in the sector.<\/p>\n<h1><span style=\"font-family: verdana, geneva, sans-serif;\">Psychedelics<\/span><\/h1>\n<h2>HAVN&#8217;s Transformational Acquisition of Spore Life Sciences<\/h2>\n<p><iframe loading=\"lazy\" title=\"Psychedelic Insights | HAVN Life Sciences (CSE: HAVN) (OTC: HAVLF) Acquires Spore Life Sciences\" width=\"696\" height=\"392\" src=\"https:\/\/www.youtube.com\/embed\/wlQQeUjkl88?feature=oembed&#038;enablejsapi=1&#038;origin=https:\/\/capital10x.com\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture\" allowfullscreen><\/iframe><\/p>\n<p><strong>HAVN Life Sciences (CSE: HAVN) (OTC: HAVLF)<\/strong> announced the acquisition of Spore Life Sciences.\u00a0 HAVN acquired a substantial business in Spore with many opportunities for synergies between their operations (e.g., manufacturing, distribution, product line expansion).<\/p>\n<p>\u201cWith this Definitive Agreement, HAVN Life is looking to strengthen its position as a leader in brain health focused nutritional supplements,\u201d says HAVN Life CEO Tim Moore.\u00a0 \u201cUpon completion of the Acquisition, we will add these high-quality formulations to the HAVN Life natural health product portfolio,\u201d he adds.<\/p>\n<p><span style=\"font-size: 12pt;\">Highlights of the Deal<\/span><\/p>\n<p>Spore joins HAVN as a profitable company: a gross profit margin of 70% compared with HAVN Life at 43%<\/p>\n<p>Spore management and other insiders have locked up shares from the deal for as long as 2 years<\/p>\n<p>If revenue milestones are hit, HAVN\u2019s revenue would grow from $20 million post deal to more than $100 million in 2.5 years, a 90% annual growth rate.<\/p>\n<p>Read our full report on the acquisition <a href=\"https:\/\/capital10x.com\/old\/havn-life-enters-into-definitive-agreement-to-acquire-spore-life-sciences\/\">here<\/a>.<\/p>\n<h2>Mindset&#8217;s Lead Candidate MSP-1014 Comparable to Psilocybin in Assay Analysis<\/h2>\n<p><strong>Mindset Pharma (CSE: MSET) (OTCQB: MSSTF) <\/strong>announced that its lead candidate, MSP-1014, was comparable to psilocybin assessed using a drug discrimination assay.\u00a0 The results suggest that MSP-1014 induces a similar perceptual state to psilocybin, further confirming the viability of MSP-1014 as a therapeutic analog of first-generation psilocybin as they advance MSP-1014 into the clinic.<\/p>\n<p>\u201cIn the drug discrimination assay, MSP-1014 demonstrated a dose dependent and full generalization to a psilocybin discriminative cue in rats,\u201d stated Joseph Araujo, CSO of Mindset.<\/p>\n<p>\u201cFurthermore, we identified an effective dosage of 0.6 mg\/kg for subcutaneous administration of MSP-1014 with no detrimental effect on the response rate up to doses of 2 mg\/kg.\u00a0 MSP-1014 also showed a dose dependent generalization to a psilocybin cue following the oral route of administration.\u00a0 These results further validate MSP-1014 as an effective second-generation psilocybin-like drug candidate.\u201d<\/p>\n<h2>Cybin Awarded Patent for Compound to Treat Anxiety<\/h2>\n<p><strong>CYBIN (NEO: CYBIN) (NYSE: CYBN)<\/strong> announced that it has been awarded a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application No. 17\/394,038 related to CYB004, their investigational deuterated psychedelic tryptamine compound for the potential treatment of anxiety disorders.\u00a0 The patent, which is expected to expire in 2041 before consideration of any patent term extension, covers composition of matter for the CYC004 drug substance as a putative new chemical entity.<\/p>\n<p>\u201cThe receipt of this Notice of Allowance from the USPTO represents an important milestone in expanding our intellectual property portfolio progressing psychedelics to therapeutics for the countless patients in need, and strongly demonstrates the Company\u2019s dedication to the discovery and development of differentiated psychedelic-based compounds for addressing mental health,\u201d said Doug Drysdale, CEO of Cybin.<\/p>\n<p>\u201cOnce issued, this patent may have the opportunity to cover a broad range of claims supporting our IP in psychedelic medicine and further strengthen our emerging best-in-class position in this evolving industry.\u201d<\/p>\n<h2>FDA Places Clinical Hold on MindMed&#8217;s Phase 2b LSD Trial<\/h2>\n<p><strong>Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED)<\/strong> announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its IND submission intended to support the initiation of a Phase 2b trial of lysergic acid diethylamide (LSD) for the treatment of generalized anxiety disorder (GAD).\u00a0 Additional detail regarding the FDA\u2019s decision is expected within 30 days.<\/p>\n<p>\u201cOur team has a tremendous sense of urgency to bring new treatments, such as LSD, to the many patients in need, particularly given to the growing mental health epidemic,\u201d said Robert Barrow, CEO and Director of MindMed.\u00a0 \u201cWe remain highly confident in the therapeutic potential of LSD to usher in a new treatment paradigm for these disorders and we look forward to working closely with FDA to satisfy all outstanding concerns as rapidly as possible.\u201d<\/p>\n<h1><span style=\"font-family: verdana, geneva, sans-serif;\">Cannabis<\/span><\/h1>\n<p><strong>The Drug Enforcement Administration (DEA)<\/strong> and National Institute on Drug Abuse (NIDA) say they are in favor of a White House proposal to streamline the process of researching Schedule I drugs like marijuana and certain psychedelics.\u00a0 The agencies testified at a House Energy and Commerce subcommittee hearing, expressing support for the Office of National Drug Control Policy (ONDCP) research plan.\u00a0 The focus of the meeting was mostly regarding a move to strictly classify fentanyl-related substances, the parts of the White House\u2019s proposal regarding research would help address concerns within the scientific community about the problems with studying other Schedule I drugs.<\/p>\n<p>\u201cIt is critical that the scientific and medical community study Schedule I substances, as some may turn out to have therapeutic value,\u201d said, DEA Principal Deputy Administrator Louis Milione. \u201cDEA supports the administration\u2019s legislative proposal\u2019s expansion of access to Schedule I research.\u00a0 DEA looks forward to continuing to work with the research community and our interagency partners to facilitate Schedule 1 research.\u201d<\/p>\n<p><strong>Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI)<\/strong>\u00a0 announced that they have acquired an additional $2.5 million of secured convertible debentures in Hyasynth.\u00a0 Proceeds of the investment are designated to advance Hyasynth\u2019s production scalability as well as investment into new cannabinoid technologies, business development efforts and company growth.<\/p>\n<p>\u201cOrganigram continues to be extremely focused on delivering meaningful innovation to cannabis consumers, which is why we are so excited about deepening our relationship with Hyasynth.\u00a0 They have achieved tremendous scientific advancement in the cannabinoid biosynthesis space with technology expected to be protected by intellectual property.\u201d, said Beena Goldenberg, CEO of Organigram.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Capital 10X Growth Navigator: Copper miners are in deep discount territory, HAVN makes a transformational acquisition, Mindset&#8217;s lead candidate comparable to psilocybin.<\/p>\n","protected":false},"author":25,"featured_media":23926,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1755,59],"tags":[1846,1848,1831,1796,1803,1297,1834,1811,846,847,1267],"class_list":{"0":"post-23988","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-growth_navigator","8":"category-metals","9":"tag-copper-miners","10":"tag-cybin","11":"tag-havn","12":"tag-hbm","13":"tag-hudbay","14":"tag-mindmed","15":"tag-mindset","16":"tag-mset","17":"tag-sierra-metals","18":"tag-smt","19":"tag-smts"},"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Capital 10X Growth Navigator - December 24th 2021 | Capital 10X<\/title>\n<meta name=\"description\" content=\"Capital 10X Growth Navigator: Copper miners are in deep discount territory, HAVN makes a transformational acquisition, Mindset&#039;s lead candidate comparable to psilocybin.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Capital 10X Growth Navigator - December 24th 2021 | Capital 10X\" \/>\n<meta property=\"og:description\" content=\"Capital 10X Growth Navigator: Copper miners are in deep discount territory, HAVN makes a transformational acquisition, Mindset&#039;s lead candidate comparable to psilocybin.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Capital 10X\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/Capital10x\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-12-24T12:42:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-12-24T15:34:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2021\/12\/mental-health-psychedelics-03.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1069\" \/>\n\t<meta property=\"og:image:height\" content=\"713\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Duane Hope\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@capital10x\" \/>\n<meta name=\"twitter:site\" content=\"@capital10x\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Duane Hope\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/\"},\"author\":{\"name\":\"Duane Hope\",\"@id\":\"https:\/\/capital10x.com\/old\/#\/schema\/person\/75fddffbd75d63e9226bc4c592e9a851\"},\"headline\":\"Capital 10X Growth Navigator &#8211; December 24th 2021\",\"datePublished\":\"2021-12-24T12:42:06+00:00\",\"dateModified\":\"2021-12-24T15:34:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/\"},\"wordCount\":1094,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/capital10x.com\/old\/#organization\"},\"image\":{\"@id\":\"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2021\/12\/mental-health-psychedelics-03.jpg\",\"keywords\":[\"Copper Miners\",\"Cybin\",\"HAVN\",\"HBM\",\"Hudbay\",\"MindMed\",\"Mindset\",\"MSET\",\"Sierra Metals\",\"SMT\",\"SMTS\"],\"articleSection\":[\"Growth Navigator\",\"Metals\"],\"inLanguage\":\"en-CA\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/#respond\"]}],\"copyrightYear\":\"2021\",\"copyrightHolder\":{\"@id\":\"https:\/\/capital10x.com\/old\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/\",\"url\":\"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/\",\"name\":\"Capital 10X Growth Navigator - December 24th 2021 | Capital 10X\",\"isPartOf\":{\"@id\":\"https:\/\/capital10x.com\/old\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2021\/12\/mental-health-psychedelics-03.jpg\",\"datePublished\":\"2021-12-24T12:42:06+00:00\",\"dateModified\":\"2021-12-24T15:34:00+00:00\",\"description\":\"Capital 10X Growth Navigator: Copper miners are in deep discount territory, HAVN makes a transformational acquisition, Mindset's lead candidate comparable to psilocybin.\",\"breadcrumb\":{\"@id\":\"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/#breadcrumb\"},\"inLanguage\":\"en-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-CA\",\"@id\":\"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/#primaryimage\",\"url\":\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2021\/12\/mental-health-psychedelics-03.jpg\",\"contentUrl\":\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2021\/12\/mental-health-psychedelics-03.jpg\",\"width\":1069,\"height\":713},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/capital10x.com\/old\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Growth Navigator\",\"item\":\"https:\/\/capital10x.com\/old\/growth_navigator\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Capital 10X Growth Navigator &#8211; December 24th 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/capital10x.com\/old\/#website\",\"url\":\"https:\/\/capital10x.com\/old\/\",\"name\":\"Capital 10X\",\"description\":\"Identifying 10X Investment Opportunities\",\"publisher\":{\"@id\":\"https:\/\/capital10x.com\/old\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/capital10x.com\/old\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/capital10x.com\/old\/#organization\",\"name\":\"Capital 10X\",\"url\":\"https:\/\/capital10x.com\/old\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-CA\",\"@id\":\"https:\/\/capital10x.com\/old\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2019\/02\/capital-10X-logo-stacked.png\",\"contentUrl\":\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2019\/02\/capital-10X-logo-stacked.png\",\"width\":128,\"height\":90,\"caption\":\"Capital 10X\"},\"image\":{\"@id\":\"https:\/\/capital10x.com\/old\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Capital10x\/\",\"https:\/\/x.com\/capital10x\",\"https:\/\/www.instagram.com\/capital10x\",\"https:\/\/www.linkedin.com\/company\/capital10x\/\",\"https:\/\/www.pinterest.com\/capital10x\",\"https:\/\/www.youtube.com\/Capital10X\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/capital10x.com\/old\/#\/schema\/person\/75fddffbd75d63e9226bc4c592e9a851\",\"name\":\"Duane Hope\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-CA\",\"@id\":\"https:\/\/capital10x.com\/old\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1e094aea10a79b65e157d5f0d9968719f11d1fafb952b910a18796349f2e38e9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1e094aea10a79b65e157d5f0d9968719f11d1fafb952b910a18796349f2e38e9?s=96&d=mm&r=g\",\"caption\":\"Duane Hope\"},\"description\":\"Duane Hope is a Partner at Capital 10X, he brings over 15 years of communications and research experience to the firm. His research and writing has appeared in publications for North American, European and Asian audiences.\",\"sameAs\":[\"http:\/\/capital10x.com\"],\"url\":\"https:\/\/capital10x.com\/old\/author\/duanehope\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Capital 10X Growth Navigator - December 24th 2021 | Capital 10X","description":"Capital 10X Growth Navigator: Copper miners are in deep discount territory, HAVN makes a transformational acquisition, Mindset's lead candidate comparable to psilocybin.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/","og_locale":"en_US","og_type":"article","og_title":"Capital 10X Growth Navigator - December 24th 2021 | Capital 10X","og_description":"Capital 10X Growth Navigator: Copper miners are in deep discount territory, HAVN makes a transformational acquisition, Mindset's lead candidate comparable to psilocybin.","og_url":"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/","og_site_name":"Capital 10X","article_publisher":"https:\/\/www.facebook.com\/Capital10x\/","article_published_time":"2021-12-24T12:42:06+00:00","article_modified_time":"2021-12-24T15:34:00+00:00","og_image":[{"width":1069,"height":713,"url":"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2021\/12\/mental-health-psychedelics-03.jpg","type":"image\/jpeg"}],"author":"Duane Hope","twitter_card":"summary_large_image","twitter_creator":"@capital10x","twitter_site":"@capital10x","twitter_misc":{"Written by":"Duane Hope","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/#article","isPartOf":{"@id":"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/"},"author":{"name":"Duane Hope","@id":"https:\/\/capital10x.com\/old\/#\/schema\/person\/75fddffbd75d63e9226bc4c592e9a851"},"headline":"Capital 10X Growth Navigator &#8211; December 24th 2021","datePublished":"2021-12-24T12:42:06+00:00","dateModified":"2021-12-24T15:34:00+00:00","mainEntityOfPage":{"@id":"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/"},"wordCount":1094,"commentCount":0,"publisher":{"@id":"https:\/\/capital10x.com\/old\/#organization"},"image":{"@id":"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2021\/12\/mental-health-psychedelics-03.jpg","keywords":["Copper Miners","Cybin","HAVN","HBM","Hudbay","MindMed","Mindset","MSET","Sierra Metals","SMT","SMTS"],"articleSection":["Growth Navigator","Metals"],"inLanguage":"en-CA","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/#respond"]}],"copyrightYear":"2021","copyrightHolder":{"@id":"https:\/\/capital10x.com\/old\/#organization"}},{"@type":"WebPage","@id":"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/","url":"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/","name":"Capital 10X Growth Navigator - December 24th 2021 | Capital 10X","isPartOf":{"@id":"https:\/\/capital10x.com\/old\/#website"},"primaryImageOfPage":{"@id":"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/#primaryimage"},"image":{"@id":"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2021\/12\/mental-health-psychedelics-03.jpg","datePublished":"2021-12-24T12:42:06+00:00","dateModified":"2021-12-24T15:34:00+00:00","description":"Capital 10X Growth Navigator: Copper miners are in deep discount territory, HAVN makes a transformational acquisition, Mindset's lead candidate comparable to psilocybin.","breadcrumb":{"@id":"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/#breadcrumb"},"inLanguage":"en-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-CA","@id":"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/#primaryimage","url":"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2021\/12\/mental-health-psychedelics-03.jpg","contentUrl":"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2021\/12\/mental-health-psychedelics-03.jpg","width":1069,"height":713},{"@type":"BreadcrumbList","@id":"https:\/\/capital10x.com\/old\/growth-navigator-december-24-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/capital10x.com\/old\/"},{"@type":"ListItem","position":2,"name":"Growth Navigator","item":"https:\/\/capital10x.com\/old\/growth_navigator\/"},{"@type":"ListItem","position":3,"name":"Capital 10X Growth Navigator &#8211; December 24th 2021"}]},{"@type":"WebSite","@id":"https:\/\/capital10x.com\/old\/#website","url":"https:\/\/capital10x.com\/old\/","name":"Capital 10X","description":"Identifying 10X Investment Opportunities","publisher":{"@id":"https:\/\/capital10x.com\/old\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/capital10x.com\/old\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-CA"},{"@type":"Organization","@id":"https:\/\/capital10x.com\/old\/#organization","name":"Capital 10X","url":"https:\/\/capital10x.com\/old\/","logo":{"@type":"ImageObject","inLanguage":"en-CA","@id":"https:\/\/capital10x.com\/old\/#\/schema\/logo\/image\/","url":"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2019\/02\/capital-10X-logo-stacked.png","contentUrl":"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2019\/02\/capital-10X-logo-stacked.png","width":128,"height":90,"caption":"Capital 10X"},"image":{"@id":"https:\/\/capital10x.com\/old\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Capital10x\/","https:\/\/x.com\/capital10x","https:\/\/www.instagram.com\/capital10x","https:\/\/www.linkedin.com\/company\/capital10x\/","https:\/\/www.pinterest.com\/capital10x","https:\/\/www.youtube.com\/Capital10X\/"]},{"@type":"Person","@id":"https:\/\/capital10x.com\/old\/#\/schema\/person\/75fddffbd75d63e9226bc4c592e9a851","name":"Duane Hope","image":{"@type":"ImageObject","inLanguage":"en-CA","@id":"https:\/\/capital10x.com\/old\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1e094aea10a79b65e157d5f0d9968719f11d1fafb952b910a18796349f2e38e9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1e094aea10a79b65e157d5f0d9968719f11d1fafb952b910a18796349f2e38e9?s=96&d=mm&r=g","caption":"Duane Hope"},"description":"Duane Hope is a Partner at Capital 10X, he brings over 15 years of communications and research experience to the firm. His research and writing has appeared in publications for North American, European and Asian audiences.","sameAs":["http:\/\/capital10x.com"],"url":"https:\/\/capital10x.com\/old\/author\/duanehope\/"}]}},"_links":{"self":[{"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/posts\/23988","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/users\/25"}],"replies":[{"embeddable":true,"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/comments?post=23988"}],"version-history":[{"count":0,"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/posts\/23988\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/media\/23926"}],"wp:attachment":[{"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/media?parent=23988"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/categories?post=23988"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/tags?post=23988"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}